Mylan CEO makes $10M in 9 months

Not bad for nine months' work. Mylan CEO and Vice Chairman Robert Coury (photo) brought down $10.3 million during fiscal 2007, which ran only nine months because the drugmaker changed its fiscal year.

Coury earned salary of about $1.12 million, stock awards of $1.15 million, and about $2.1 million in incentive compensation, the Pittsburgh Business Times reports. During the previous fiscal year, Coury was paid about $8.6 million. How does this compare to other drugmakers' executive pay? Well, it beats Pfizer's Jeff Kindler ($9.5 million) but doesn't outstrip Bristol-Myers Squibb's Jim Cornelius ($11.3 million) or even Cephalon's Frank Baldino ($13.5 million).

- read the Business Times story

ALSO: A federal appeals court affirmed a ruling that prevents Mylan from selling a copycat form of Johnson & Johnson's Topamax before the epilepsy med's patent expires later this year. Report

Related Articles:
Mylan CEO intent on new global biz. Report
Glaxo to let Mylan make generic Paxil. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.